Fisher & Paykel Healthcare (ASX:FPH) has upgraded its revenue and earnings guidance for the 2026 financial year ending March 31.
Driven by robust performance in its Hospital product range and favourable exchange rate shifts, the company now anticipates full-year operating revenue of approximately NZ$2.30 billion.
This marks an increase from the previous guidance of NZ$2.17 billion to NZ$2.27 billion issued in November 2025.
The net profit after tax is now projected to fall between NZ$450 million and NZ$470 million, up from the earlier forecast of NZ$410 million to NZ$460 million.
CEO Lewis Gradon attributed the momentum to "pleasing progress" in shifting clinical practices and significant efficiency gains that have bolstered both gross and operating margins.
While seasonal respiratory hospitalisations in the Northern Hemisphere remain a variable for the second half, the company’s internal improvements have provided a solid buffer.
The updated figures notably exclude potential windfalls from the recent US Supreme Court ruling, which invalidated certain tariffs under the International Emergency Economic Powers Act.
While the company is navigating the complexities of potential refunds and free trade agreements, it maintains that current tariff structures will not materially impact its long-term strategy or sustainable growth.